Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.

Baniandrés-Rodríguez, OfeliaVilar-Alejo, JaimeRivera, RaquelCarrascosa, José ManuelDaudén, EstebanHerrera-Acosta, EnriqueSahuquillo-Torralba, AntonioGómez-García, Fran JNieto-Benito, Lula Maríade la Cueva, PabloLópez-Estebaranz, José LuisBelinchón, IsabelFerrán Farrés, MartaAlsina, MercèFernández-Freire, Lourdes RodríguezCarretero, GregorioGarcía-Donoso, CarmenBallescá, FerránLlamas-Velasco, MarHerrera-Ceballos, EnriqueBotella-Estrada, RafaelRuiz-Genao, Diana PatriciaRiera-Monroig, JosepDescalzo Gallego, Miguel ÁngelGarcía-Doval, IgnacioBIOBADADERM Study Group2023-02-092023-02-092020-10-26http://hdl.handle.net/10668/16501enAdultAgedCOVID-19Cohort StudiesFemaleHumansIncidenceMaleMiddle AgedPsoriasisRegistriesSeverity of Illness IndexSpainIncidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.research article33122022open access10.1016/j.jaad.2020.10.0461097-6787PMC7587130http://www.jaad.org/article/S0190962220328589/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587130/pdf